发布求助
文献互助 智能选刊 最新文献

Medical Letter on Drugs and Therapeutics最新文献

筛选
英文 中文
Zilucoplan (Zilbrysq) for myasthenia gravis. 治疗重症肌无力的 Zilucoplan（Zilbrysq）。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2024-04-15 DOI: 10.58347/tml.2024.1700c
{"title":"Zilucoplan (Zilbrysq) for myasthenia gravis.","authors":"","doi":"10.58347/tml.2024.1700c","DOIUrl":"https://doi.org/10.58347/tml.2024.1700c","url":null,"abstract":"","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140854445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Donislecel (Lantidra) for type 1 diabetes. 治疗 1 型糖尿病的 Donislecel（Lantidra）。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2024-04-15 DOI: 10.58347/tml.2024.1700d
{"title":"Donislecel (Lantidra) for type 1 diabetes.","authors":"","doi":"10.58347/tml.2024.1700d","DOIUrl":"https://doi.org/10.58347/tml.2024.1700d","url":null,"abstract":"","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140874179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drugs for bipolar disorder. 治疗躁郁症的药物。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2024-04-01 DOI: 10.58347/tml.2024.1699a
{"title":"Drugs for bipolar disorder.","authors":"","doi":"10.58347/tml.2024.1699a","DOIUrl":"https://doi.org/10.58347/tml.2024.1699a","url":null,"abstract":"","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140872147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Addendum: Bupropion safety in pregnancy. 增编：妊娠期服用安非他酮的安全性。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2024-04-01 DOI: 10.58347/tml.2024.1699c
{"title":"Addendum: Bupropion safety in pregnancy.","authors":"","doi":"10.58347/tml.2024.1699c","DOIUrl":"https://doi.org/10.58347/tml.2024.1699c","url":null,"abstract":"","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140860507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Omalizumab (Xolair) for food allergy. 治疗食物过敏的奥马珠单抗（Xolair）。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2024-04-01 DOI: 10.58347/tml.2024.1699b
{"title":"Omalizumab (Xolair) for food allergy.","authors":"","doi":"10.58347/tml.2024.1699b","DOIUrl":"https://doi.org/10.58347/tml.2024.1699b","url":null,"abstract":"","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140867334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cantharidin topical solution (Ycanth) for molluscum contagiosum. 治疗传染性软疣的坎他立定外用溶液（Ycanth）。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2024-02-19 DOI: 10.58347/tml.2024.1696b
{"title":"Cantharidin topical solution (Ycanth) for molluscum contagiosum.","authors":"","doi":"10.58347/tml.2024.1696b","DOIUrl":"10.58347/tml.2024.1696b","url":null,"abstract":"","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139984531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Daprodustat (Jesduvroq) for anemia of chronic kidney disease. 治疗慢性肾病贫血的达普罗达（Jesduvroq）。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2024-02-19 DOI: 10.58347/tml.2024.1696a
{"title":"Daprodustat (Jesduvroq) for anemia of chronic kidney disease.","authors":"","doi":"10.58347/tml.2024.1696a","DOIUrl":"10.58347/tml.2024.1696a","url":null,"abstract":"","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139984533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Balfaxar: Another four-factor PCC for warfarin reversal. Balfaxar：另一种用于华法林逆转的四因子 PCC。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2024-02-19 DOI: 10.58347/tml.2024.1696d
{"title":"Balfaxar: Another four-factor PCC for warfarin reversal.","authors":"","doi":"10.58347/tml.2024.1696d","DOIUrl":"10.58347/tml.2024.1696d","url":null,"abstract":"","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139984530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fruquintinib (Fruzaqla) for metastatic colorectal cancer. 治疗转移性结直肠癌的 Fruquintinib（Fruzaqla）。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2024-02-19 DOI: 10.58347/tml.2024.1696f
{"title":"Fruquintinib (Fruzaqla) for metastatic colorectal cancer.","authors":"","doi":"10.58347/tml.2024.1696f","DOIUrl":"10.58347/tml.2024.1696f","url":null,"abstract":"","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139984534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Repotrectinib (Augtyro) for non-small cell lung cancer. 治疗非小细胞肺癌的瑞博替尼（Augtyro）。
IF 1.9 4区 医学
Medical Letter on Drugs and Therapeutics Pub Date : 2024-02-19 DOI: 10.58347/tml.2024.1696g
{"title":"Repotrectinib (Augtyro) for non-small cell lung cancer.","authors":"","doi":"10.58347/tml.2024.1696g","DOIUrl":"10.58347/tml.2024.1696g","url":null,"abstract":"","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139984535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信